The application period will run from Jan. 12, 2026 to March 31, 2026 at 2 p.m. EST.
The Tax Incentive Program supports companies engaged in life sciences research and development, commercialization and manufacturing in Massachusetts. The program provides incentives to companies, of all sizes, looking to expand their efforts by creating new, long-term jobs in Massachusetts.
Up to $40 million in tax incentives are available for the current program round.
Interested applicants are required to submit an online application. This is a one-step application process that includes all the information necessary for the applicant company to be certified under the Life Sciences Act.
Please see sections 5 and 6 of the Solicitation for more information regarding the application process and further details on the eligibility requirements.
Companies that receive a tax incentive award are required to provide Annual Reports to monitor the progress of the hiring and retention against the commitment levels, which were the basis of the award provided.
Companies not in compliance with their hiring commitments will be decertified. Decertified companies must return tax incentives to the Massachusetts Department of Revenue.
Please see Policies section below for the program policies regarding reporting, acquisitions, divestiture, and termination of incentives.
To ensure the Massachusetts’ ecosystem stays the hotbed for life sciences activity, we will continue to make investments through our Tax Incentive program to create jobs, build a robust workforce, and propel the development of new therapies, devices, and scientific advancements that are improving patient health and well-being.
Olaris is a precision diagnostics company that is on a mission to revolutionize how diseases are diagnosed and treated. By leveraging their CEREBRO platform (Comprehensive Early Responsive Evaluation of Biomarkers Related to Outcomes), which combines metabolomics and machine learning, they are able to harness the power of the body’s own communication system to discover and develop their pipeline of myOLARIS precision diagnostics.
